search
Back to results

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

Primary Purpose

AML M4, AML M5

Status
Recruiting
Phase
Early Phase 1
Locations
China
Study Type
Interventional
Intervention
anti-ILT3 CAR-T
Sponsored by
Carbiogene Therapeutics Co. Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for AML M4

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female patients, aged ≥18 years or ≤70 years;
  2. Acute myeloid leukemia AML M4/M5 subtype was diagnosed according to Fab standard classification, confirmed by bone marrow IHC or ILT3-positive expression by flow cytometry in monocytes (primary and young monocytes in bone marrow ≥20%)
  3. Relapsed/refractory patients, whose conditions meet:

    • Recurrent AML diagnosis standard: complete remission (CR) after the original cells in peripheral blood again leukemia cells or bone marrow > 0.050 (with the exception of consolidation chemotherapy after bone marrow regeneration for other reasons) or myeloid leukemia cells infiltrating outside.
    • Refractory AML diagnostic criteria: after two standard regimen for treatment invalid early cure; patients who relapsed within 12 months after consolidation and intensive treatment after CR; relapsed after 12 months but failed to respond to conventional chemotherapy; 2 or more recurrences; patients with persistent extramedullary leukemia.
  4. Main organ functions meet the following conditions:

    • Kidney function: creatinine clearance (absolute value) or 60 ml/min or creatinine < 2.0 mg/dl or < 2 times the subjects' age group upper limit of normal (ULN) blood.
    • Liver function: ALT ≤ 3 or less ULN, AST ≤ 3 or less ULN.
    • Heart function: the ejection fraction ≥ 50%, measured by echocardiography (ECHO) or more acquisition scan (MUGA).
    • Lung function: no clinical significance of pleural effusion, baseline blood oxygen saturation > 92%.
  5. ECOG physical status score 0-3.
  6. No use of steroid hormones within 2 weeks.
  7. Sufficient venous access to single or venous blood collection is available, and there are no other contraindications to blood cell separation.
  8. Signed written informed consent form.

Exclusion Criteria:

Subjects will not be included in the study if they meet any of the following criteria:

  1. Pregnant or lactating women;
  2. HIV serological positive;
  3. Active bacterial, fungal or viral infections that are not controlled by treatment;
  4. Suffer from coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage or other serious cardiovascular and cerebrovascular diseases;
  5. History and concomitant diseases:

    • Subjects with known or suspected autoimmune diseases or immunodeficiency diseases;
    • Subjects requiring systemic treatment with corticosteroids or other immunosuppressive agents during treatment;
    • Subjects who have previously received other gene therapies;
    • Subjects with a history of organ transplantation (referring to solid organ transplantation);
    • Subjects with severe mental disorders;
    • Participated in other clinical studies within one month before the collection of PBMC;
    • Uncontrolled active hepatitis B and/or C infection (hepatitis B: HBV DNA > 500 IU/ml or copy number > 2500 copies /ml;
    • Hepatitis C: HCV antibody positive and HCV-RNA levels above the detection limit);
    • Any serious or uncontrolled disease that the Investigator considers to be likely to increase the risk associated with study participation, study drug administration, or affect the subject's ability to receive the study drug;
    • Subjects who underwent major surgery or suffered significant trauma within 4 weeks prior to the collection of PBMCs, or who are expected to require major surgery during the study period.

Sites / Locations

  • Zhejiang Provincal People's HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Anti-ILT3 CAR-T cells

Arm Description

All subjects were intravenous administrated with anti-ILT3 CAR-T cells

Outcomes

Primary Outcome Measures

Rate of grade 3 or 4 treatment related adverse effects
All the CAR-T treatment related adverse events,including Dose limiting toxicity (DLT), cytokine release syndrome (CRS), CAR-T associated encephalopathy syndrome, will be assessed and graded by NCI CTCAE v 5.0.
Implantation endpoint
To assess the duration of CAR-positive T cells in circulation, the copy number of CAR DNA was measured at the preset follow-up time point. The time when the results of any two consecutive tests were negative, were recorded as the "implantation endpoint"

Secondary Outcome Measures

Disease specific response
Disease specific response includes, but are not limited to, complete response (CR) including morphological leukemia-free status, morphological CR, cytogenetic CR, molecular CR, and partial response (PR).
Overall survival
From date of inclusion to date of progression, relapse, or death from any cause
Progress-free survival
The length of time that a participant's disease did not progress during and after CAR-T treatment
CAR-T residue
The residue of CAR-positive T cells in circulation determined by flow cytometry
Minimal residual disease (MRD)
MRD is a status that none tumor cells can be detected by standard cell morphology.

Full Information

First Posted
March 15, 2021
Last Updated
March 19, 2021
Sponsor
Carbiogene Therapeutics Co. Ltd.
Collaborators
Zhejiang Provincial People's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04803929
Brief Title
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
Official Title
Clinical Study of Autologous T Cells Modified With ILT3 Chimeric Antigen Receptor for Relapsed/Refractory Acute Myeloid Leukemia (M4/M5)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Recruiting
Study Start Date
March 3, 2021 (Actual)
Primary Completion Date
March 1, 2024 (Anticipated)
Study Completion Date
March 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Carbiogene Therapeutics Co. Ltd.
Collaborators
Zhejiang Provincial People's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the safety and efficacy of novel ILT3-targeted CAR-T cell therapy for patients with relapsed or refractory acute myeloid leukemia (M4/M5).
Detailed Description
Our group has developed a novel anti-ILT3 CAR T cell therapy, and this pilot study is focused on the safety and efficacy of the anti-ILT3 CAR-T for R/R AML(M4/M5) patients. A total of 25 subjects are intravenously adminstered with anti-ILT3 CAR-T cells. The dosages of CAR-T cells follow the "3+3" dose increment program.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
AML M4, AML M5

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Anti-ILT3 CAR-T cells
Arm Type
Experimental
Arm Description
All subjects were intravenous administrated with anti-ILT3 CAR-T cells
Intervention Type
Biological
Intervention Name(s)
anti-ILT3 CAR-T
Intervention Description
Autologous T cells genetically modified with anti-ILT3 CAR
Primary Outcome Measure Information:
Title
Rate of grade 3 or 4 treatment related adverse effects
Description
All the CAR-T treatment related adverse events,including Dose limiting toxicity (DLT), cytokine release syndrome (CRS), CAR-T associated encephalopathy syndrome, will be assessed and graded by NCI CTCAE v 5.0.
Time Frame
up to 24 weeks after first infusion
Title
Implantation endpoint
Description
To assess the duration of CAR-positive T cells in circulation, the copy number of CAR DNA was measured at the preset follow-up time point. The time when the results of any two consecutive tests were negative, were recorded as the "implantation endpoint"
Time Frame
up to 2 years after first infusion
Secondary Outcome Measure Information:
Title
Disease specific response
Description
Disease specific response includes, but are not limited to, complete response (CR) including morphological leukemia-free status, morphological CR, cytogenetic CR, molecular CR, and partial response (PR).
Time Frame
up to 2 years after first infusion
Title
Overall survival
Description
From date of inclusion to date of progression, relapse, or death from any cause
Time Frame
up to 2 years after inclusion
Title
Progress-free survival
Description
The length of time that a participant's disease did not progress during and after CAR-T treatment
Time Frame
up to 2 years after inclusion
Title
CAR-T residue
Description
The residue of CAR-positive T cells in circulation determined by flow cytometry
Time Frame
up to 2 years after first infusion
Title
Minimal residual disease (MRD)
Description
MRD is a status that none tumor cells can be detected by standard cell morphology.
Time Frame
up to 2 years after first infusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients, aged ≥18 years or ≤70 years; Acute myeloid leukemia AML M4/M5 subtype was diagnosed according to Fab standard classification, confirmed by bone marrow IHC or ILT3-positive expression by flow cytometry in monocytes (primary and young monocytes in bone marrow ≥20%) Relapsed/refractory patients, whose conditions meet: Recurrent AML diagnosis standard: complete remission (CR) after the original cells in peripheral blood again leukemia cells or bone marrow > 0.050 (with the exception of consolidation chemotherapy after bone marrow regeneration for other reasons) or myeloid leukemia cells infiltrating outside. Refractory AML diagnostic criteria: after two standard regimen for treatment invalid early cure; patients who relapsed within 12 months after consolidation and intensive treatment after CR; relapsed after 12 months but failed to respond to conventional chemotherapy; 2 or more recurrences; patients with persistent extramedullary leukemia. Main organ functions meet the following conditions: Kidney function: creatinine clearance (absolute value) or 60 ml/min or creatinine < 2.0 mg/dl or < 2 times the subjects' age group upper limit of normal (ULN) blood. Liver function: ALT ≤ 3 or less ULN, AST ≤ 3 or less ULN. Heart function: the ejection fraction ≥ 50%, measured by echocardiography (ECHO) or more acquisition scan (MUGA). Lung function: no clinical significance of pleural effusion, baseline blood oxygen saturation > 92%. ECOG physical status score 0-3. No use of steroid hormones within 2 weeks. Sufficient venous access to single or venous blood collection is available, and there are no other contraindications to blood cell separation. Signed written informed consent form. Exclusion Criteria: Subjects will not be included in the study if they meet any of the following criteria: Pregnant or lactating women; HIV serological positive; Active bacterial, fungal or viral infections that are not controlled by treatment; Suffer from coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage or other serious cardiovascular and cerebrovascular diseases; History and concomitant diseases: Subjects with known or suspected autoimmune diseases or immunodeficiency diseases; Subjects requiring systemic treatment with corticosteroids or other immunosuppressive agents during treatment; Subjects who have previously received other gene therapies; Subjects with a history of organ transplantation (referring to solid organ transplantation); Subjects with severe mental disorders; Participated in other clinical studies within one month before the collection of PBMC; Uncontrolled active hepatitis B and/or C infection (hepatitis B: HBV DNA > 500 IU/ml or copy number > 2500 copies /ml; Hepatitis C: HCV antibody positive and HCV-RNA levels above the detection limit); Any serious or uncontrolled disease that the Investigator considers to be likely to increase the risk associated with study participation, study drug administration, or affect the subject's ability to receive the study drug; Subjects who underwent major surgery or suffered significant trauma within 4 weeks prior to the collection of PBMCs, or who are expected to require major surgery during the study period.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lai Jin
Phone
+86-18458227035
Email
hjdl188@sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jianping Lan
Organizational Affiliation
Zhejiang Provincial People's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zhejiang Provincal People's Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lai Jin
Phone
+86-18458227035
Email
hjdl188@sina.com
First Name & Middle Initial & Last Name & Degree
Jianping Lan

12. IPD Sharing Statement

Learn more about this trial

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

We'll reach out to this number within 24 hrs